First U.S. Patient Successfully Treated for Alcoholism with CITA Biomedical's Innovative Program to End Alcohol Dependence
Treated in Just Two Days, Patient Suffered No Withdrawal Symptoms and After Treatment had No Cravings for Alcohol
Beverly Hills, Calif., July 9, 2002 - CITA Biomedical, Inc. (OTCBB:DTOX) a growing leader in the treatment of substance dependency, today announced that the first U.S. Detoxification and Neuro-Adaptation (DNA) for Alcohol patient was successfully treated for alcohol dependence. DNA for Alcohol is a part of a family of treatments called DNA for Addictions.
The patient, a 62-year-old male who had been dependant on alcohol for over 40 years was treated with DNA for Alcohol. The patient was consuming an average of 1.5 liters of gin, brandy, and beer a day. The treatment was administered to the patient over two consecutive days where the patient experienced no symptoms of withdrawal. After treatment the patient said he felt an overwhelming sense of happiness, had no cravings for alcohol, and mental clarity that he had not felt for years.
DNA for Alcohol establishes a new treatment regimen in the fight against alcoholism, a disorder that impedes normal neural functioning of the brain and body systems as a whole. Alcoholism causes cravings, possible brain damage, and can lead to potentially life-threatening withdrawal symptoms. Historically, the disorder of alcoholism has been treated only through behavioral intervention, but the CITA DNA treatment provides a solution for treating both the physiological and psychological components of this devastating condition.
The patients that were treated in Europe last year experienced a less than 25 percent relapse rate, compared to a more than 75 percent relapse rate generally associated other accepted means of treating alcoholism. The new treatment was also shown to reduce the time, pain, and costs associated with withdrawal, and allowed the patients to return to a productive level of functioning within hours of the treatment’s completion.
"We are pleased to bring the proven safe and effective DNA for Addictions treatments to the U.S. Years in development and extremely successful with our CITA affiliate in Europe, we feel DNA for Addictions will revolutionize the treatment of substance dependence worldwide.” said Joseph Dunn, president and CEO of CITA Biomedical. We anticipate that this patient will be the first of thousands that we will treat for alcohol dependence in the coming year. Our mission is to make the transition from substance dependence to independence as smooth and humane as possible and with DNA for Addictions we’ve done that.”
The DNA for Addictions treatment family includes DNA for Alcohol, DNA for Alcohol and Cocaine, DNA for Cocaine, and DNA for Crack Cocaine. CITA has patents pending for the family of DNA treatments.
About CITA Biomedical, Inc.
CITA Biomedical, Inc., headquartered in Beverly Hills, Calif., focuses on the innovative treatment of addiction. The company holds the U.S. patent for its successful UROD (Ultra Rapid Opiate Detoxification) treatment method. UROD is the only clinically tested and effective treatment method to rapidly detoxify individuals addicted to opiate-based drugs, including heroin within four to six hours with few, if any, withdrawal symptoms. The company recently announced a new family of revolutionary treatments, Detoxification and NeuroAdaptation (DNA) for Addictions. The first treatments from this family treat alcohol, cocaine, and poly-drug addictions. To date, CITA has grown it’s business through internal expansion and now seeks compatible, leading, and complementing technologies and acquisitions to enhance it’s corporate portfolio. CITA Biomedical, Inc. has two operating divisions CITA Americas, Inc., and AltTPro, Inc. For more information, please visit citabio.com
UROD is a registered trademark of CITA Biomedical, Inc.
Contacts:
CITA Biomedical, Inc.
Judy Ryon, 310-550-4971 jryon@citabio.com
Vision Corporate Consulting
Laurel Moody, 212-446-6109 laurel@visioncc.net
. |
